CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Arhalofenate +3 moredrug
Likely dose
Arhalofenate 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01399008
NCT01399008Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in Combination With Allopurinol in Gout Patients With an Inadequate Hypouricemic Response to Allopurinol Alone

Gilead Sciences·interventional·Posted Jul 21, 2011·Updated Sep 18, 2015

In Brief

A Phase 2 clinical trial evaluating Arhalofenate, Allopurinol, and 2 other interventions for Gout. Completed, enrolled 100 participants across 24 sites in 3 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesCanada, Georgia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 21, 2011
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.9 years ago

Interventions

Arhalofenatedrug

Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks

Allopurinoldrug

Allopurinol 300 mg as active comparator

Colchicinedrug

0.6 mg colchicine daily as flare prophylaxis

Placebodrug

Placebo